ASND
$228.06
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Intraday
Recent News
Ascendis Pharma Gains FDA Nod For Yuviwel And New Growth Prospects
FDA granted accelerated approval for Yuviwel, a once-weekly therapy for children with achondroplasia. Yuviwel is the first weekly option in this indication, ending a competitor's monopoly with a daily treatment. The approval includes a Rare Pediatric Disease Priority Review Voucher, adding potential value for Ascendis Pharma. This decision positions Ascendis Pharma (NasdaqGS:ASND) as a key player in achondroplasia treatment. Ascendis Pharma, listed on NasdaqGS:ASND, focuses on rare...
Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference
Ascendis Pharma A/S (NASDAQ:ASND) discussed plans to launch its newly approved achondroplasia therapy YUVIWEL during a virtual fireside chat at the 46th annual TD Cowen Healthcare Conference, held shortly after the company’s U.S. approval announcement. YUVIWEL launch timing and readiness Management
Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia
Ascendis Pharma A/S (NASDAQ:ASND) executives outlined plans for the U.S. launch of YUVIWEL following FDA approval, describing the product as the first once-weekly treatment for children with achondroplasia and emphasizing its label, clinical profile, and expected near-term commercialization steps.
This Biopharma Stock Flirts With Buy Point After New FDA Approval
This genetic disorder treatment developer stock is nearing a buy point of a base. The biopharmaceutical got FDA approval on a new treatment.
Ascendis Wins FDA Approval For Rare Disease Therapy
Ascendis Pharma A/S shares are up during Monday’s premarket session following the FDA’s approval of Yuviwel (navepegritide; developed as TransCon CNP), the first and only once-weekly treatment for children with achondroplasia. FDA Approval The FDA approved Yuviwel, a prodrug designed to increase linear growth in children aged two years and older with achondroplasia, based on data from three randomized clinical trials. Achondroplasia is a rare genetic disorder causing dwarfism, characterized by s